The US Might Not Have Enough Glass Vials To Distribute the Coronavirus Vaccines
The COVID-19 vaccination plan may hit a serious supply chain issue.
When a COVID-19 vaccine is finally ready, the pharmaceutical industry may face an even bigger challenge: Actually getting it into the hands and bloodstreams of the public.
That’s because there aren’t nearly enough medical-grade glass vials to distribute the vaccine, Wired reports. And making up the deficit on such a short time frame would vastly exceed what manufacturers are currently capable of doing.
Medical glass needs to be made from a particular kind of sand — its jagged edges make vials that are resilient against both physical damage and temperature changes, all while not interacting with the sensitive chemicals stored inside. Wired reports that this particular sand is in high demand, as it’s also used in things like concrete and solar panels, so the pharmaceutical industry may not be able to scrape together enough to send out a vaccine.
But scientists are trying to find workarounds. Christopher Weikart, the chief scientists at SiO2 Materials Science, told Wired that he’s found a way to etch an inner glass lining into plastic bottles using plasma.
Weikart found that he could pack plastic bottles full of silicon dioxide gas and then ionize it by zapping it with an electric current. Over time, part of the gas sticks to the plastic bottle and forms a glass layer around the inside.
It’s a neat trick, and one that could help fight supply chain problems. But, just like the medical glass shortages hitting the industry in the first place, the challenge will be finding a way to bring it up to scale.
Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at UnderstandSolar.com. By signing up through this link, Futurism.com may receive a small commission.
Share This Article
READ MORE: Vaccine Makers Turn to Microchip Tech to Beat Glass Shortages [Wired]
More on coronavirus vaccines: With No Patients At Home, China Outsources COVID Vaccine Trials